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The FANCD2–FANCI complex is recruited to DNA
interstrand crosslinks before monoubiquitination
of FANCD2
Chih-Chao Liang1, Zhuolun Li2, David Lopez-Martinez1, William V. Nicholson1, Catherine Ve´nien-Bryan2
& Martin A. Cohn1
The Fanconi anaemia (FA) pathway is important for the repair of DNA interstrand crosslinks
(ICL). The FANCD2–FANCI complex is central to the pathway, and localizes to ICLs
dependent on its monoubiquitination. It has remained elusive whether the complex is
recruited before or after the critical monoubiquitination. Here, we report the ﬁrst structural
insight into the human FANCD2–FANCI complex by obtaining the cryo-EM structure. The
complex contains an inner cavity, large enough to accommodate a double-stranded DNA
helix, as well as a protruding Tower domain. Disease-causing mutations in the Tower domain
are observed in several FA patients. Our work reveals that recruitment of the complex to a
stalled replication fork serves as the trigger for the activating monoubiquitination event. Taken
together, our results uncover the mechanism of how the FANCD2–FANCI complex activates
the FA pathway, and explains the underlying molecular defect in FA patients with mutations in
the Tower domain.
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F
anconi anaemia (FA) is a genetic disorder characterized by
developmental defects, cancer susceptibility and a severe
cellular sensitivity to agents inducing toxic interstrand
crosslinks (ICLs) formed between the two strands of the
Watson–Crick DNA helix. A total of 19 FA proteins function
together in a complex pathway leading to the repair of an ICL,
primarily in the S-phase of the cell cycle1. Central to the pathway
is the FANCD2–FANCI protein complex, recruitment of
which to the ICL is critical for repair. It is known that
monoubiquitination of FANCD2 is indispensable to a
functional pathway2, and several studies demonstrate how
monoubiquitinated FANCD2 facilitates recruitment of the
FAN1 (refs 3–5), and XPF-ERCC1 (refs 6,7) nucleases to
the ICL, providing a molecular explanation for why
monoubiquitination of FANCD2 is critical to the pathway. The
underlying mechanism for recruitment of the FANCD2–FANCI
complex itself to the ICL is currently unclear.
Whereas the structure of the mouse homologues has been
reported8, to date there is no structural information on the
human FANCD2–FANCI complex. Here, we present a cryo-EM
structure of the full-length human FANCD2–FANCI complex,
demonstrating the existence of a novel Tower domain. The Tower
domain is required for recruitment of the complex to ICLs
in vitro and in vivo. We also demonstrate, for the ﬁst time, a
direct interaction between the FANCD2–FANCI complex and a
DNA structure resembling a replication fork stalled at an ICL.
Finally, we present data ﬁrmly establishing that the FANCD2–
FANCI complex needs to be bound to DNA, to be efﬁciently
monoubiquitinated. Several FA disease-causing mutations lie
within the Tower domain, thus we have uncovered the molecular
basis for the disease in these patients.
Results
Cryo-EM structure of the full-length FANCD2–FANCI complex.
To gain further insight into the mechanism of FANCD2–FANCI
function during ICL repair, we decided to obtain structural
insight of the full-length human complex by electron microscopy
(EM). We co-expressed Flag-HA-tagged human FANCD2 and
His-tagged human FANCI in Sf9 cells and puriﬁed the hetero-
dimeric complex to homogeneity (Fig. 1a). The intensities of
FANCD2 and FANCI in the Coomassie-stained gel appear
identical. The highly pure complex was then subjected to EM
analysis using negative stain. Representative micrographs of the
grids demonstrated homogeneity of the sample (Supplementary
Fig. 1a,b). In all, 4,082 pairs of particles were used to calculate a
three-dimensional (3D) model using the random conical tilt
method (RCT)9.
We then subjected the FANCD2–FANCI complex to cryo-EM
to reﬁne this preliminary 3D model. A micrograph shows
homogeneity of the sample (Supplementary Fig. 2a), from which
we obtained a structure with a resolution of 22Å, allowing
the determination of further details of the structure. The
3D-reconstruction revealed a 90Å wide and 160Å long structure
with a hollow central part. We also observed a characteristic 60Å
protruding domain, which we termed as the Tower domain
(Fig. 1b). We noticed that the end of the Tower domain adapts a
fork-like structure. When comparing our determined structure
with the crystal structure of the mouse FANCD2–FANCI
complex8, we noticed a striking difference. While the position
of the Tower domain is vertical in our structure, it adapts a
horizontal position in the crystal structure (Fig. 1c). When we
dock the crystal structure onto the cryo-EM structure, allowing
ﬂexibility of each of the eight solenoids in the crystal structure
relative to each other, we observe good agreement between the
two structures (Fig. 1d). The difference in the position of the
Tower domain in the two structures could be a result of the two
different methods used to obtain the structures. The crystal
structure is based on a version of FANCD2 containing three
relatively large deletions, whereas the EM structure is based on
the full-length protein, which might also contribute to the
observed differences. The position of the Tower domain
suggested that it is composed of the C-terminus of FANCD2.
To test this directly, we introduced a C-terminal deletion in
FANCD2 containing the last 305 amino acids (Fig. 2a), and
puriﬁed the complex of this protein (FANCD2DTower) and
FANCI (Fig. 2b). The highly puriﬁed FANCD2DTower-FANCI
heterodimer was subjected to cryo-EM, resulting in a structure at
20Å resolution clearly missing the Tower domain, but otherwise
similar to the full-length structure (Fig. 2c,d). These data are
further conﬁrmed by docking the mouse crystal structure, where
we have removed the C-terminal 305 amino acids onto the cryo-
EM structure of the FANCD2DTower–FANCI complex
(Supplementary Fig. 2b).
The Tower domain is important for the FANCD2–FANCI
complex. Given the striking position of the Tower domain,
we decided to determine whether this domain is functionally
important to the FANCD2–FANCI complex, and to the FA
pathway. We stably expressed exogenous full-length FANCD2 or
FANCD2DTower in patient-derived FANCD2-deﬁcient PD20
cells (Supplementary Fig. 3a). The ability of these cell lines to
survive under increasing concentrations of the ICL-inducing
drug mitomycin C (MMC) was then assessed. We found that
non-complemented cells were very sensitive to MMC, and that
expression of the full-length protein restored resistance (Fig. 3a).
On the other hand, expression of the FANCD2DTower protein
did not complement the cells, demonstrating the functional
importance of the Tower domain (Fig. 3a).
Monoubiquitination of FANCD2 is necessary for its ICL
DNA-repair function. We speculated that the Tower domain
might affect the ability of FANCD2 to be monoubiquitinated,
and that this could be part of the mechanism underlying its
function in the pathway. We assessed the ability of the FANCD2
and FANCD2DTower proteins expressed in PD20 cells to be
monoubiquitinated. As expected, full-length FANCD2 was
strongly ubiquitinated in response to MMC (Fig. 3b, lane 10).
In contrast, the FANCD2DTower protein was not ubiquitinated
at all (Fig. 3b, lane 12). Also, we observed a nice restoration of
FANCI ubiquitination when full-length FANCD2 was expressed,
but no ubiquitination of FANCI when the FANCD2DTower
protein was expressed. The absence of ubiquitination of FANCD2
could be due to lack of interaction with its E3 ubiquitin ligase
complex (core complex). However, both full-length and the
Tower-deletion protein interact equally well with the core
complex (Supplementary Fig. 3b). Since the Tower domain is
important for the function of FANCD2, and also for its
monoubiquitination, we next assessed whether the Tower domain
is important for the recruitment of FANCD2 to ICLs in vivo. To
this end we utilized a live-cell imaging system that we have
previously described10. We reduced the cellular levels of
endogenous FANCD2 in HeLa cells by shRNA and then
stably expressed exogenous shRNA-resistant EGFP-tagged either
full-length FANCD2 or FANCD2DTower (Supplementary
Fig. 3c), and conﬁrmed the established cell lines by clonogenic
survival assays (Supplementary Fig. 3d). Full-length FANCD2
was recruited to ICLs as expected, forming clear stripes 10min
after the introduction of the ICLs (Fig. 3c). Strikingly, deletion of
the Tower domain completely abolished the recruitment (Fig. 3c).
The Tower domain is needed for recruitment of FANCD2 to ICLs.
Since the Tower domain is functionally important, due to its
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requirement for monoubiquitination of FANCD2, and its role in
the recruitment of FANCD2 to ICLs in vivo, we speculated
that this domain might be involved in the interaction of the
FANCD2–FANCI complex with DNA. To test this directly, we
assessed the ability of the FANCD2–FANCI and FANCD2D
Tower–FANCI complexes to interact with DNA. It is presumed
that the FANCD2–FANCI complex is recruited to replication
forks stalled at an ICL. Therefore, we synthesized a DNA
molecule mimicking a replication fork and evaluated the abilities
of the two complexes to interact with it. FANCD2–FANCI
formed a speciﬁc complex with the DNA, which could be super-
shifted using speciﬁc antibodies (Fig. 4a, lanes 2–3). On the
other hand, FANCD2DTower–FANCI formed a much weaker
complex with the DNA, demonstrating the importance of the
Tower domain in the protein–DNA interaction (Fig. 4a,
lanes 4–5). To gain further insight into the mechanism of the
interaction, we next synthesized a similar DNA molecule, but
now containing an ICL in the fork, more realistically representing
a replication fork stalled at an ICL. Using this molecule, we again
observed near abrogation of DNA binding when the Tower
domain was deleted (Fig. 4b). Interestingly, we found that
FANCD2–FANCI interacted signiﬁcantly stronger with the fork
containing an ICL, than with the non-crosslinked counterpart.
Titrating the amount of protein in the binding reaction conﬁrmed
the observed preference (Fig. 4c).
FANCD2–FANCI is recruited to DNA before ubiquitination.
Our data demonstrate a direct interaction between the
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Figure 1 | Cryo-EM structure of the FANCD2–FANCI complex. (a) Coomassie blue stain of recombinant full-length FANCD2–FANCI heterodimer puriﬁed
from Sf9 cells. (b) Cryo-EM density map of full-length FANCD2–FANCI complex in different orientations. Scale bar, 20Å. (c) Comparison of full-length
FANCD2–FANCI Cryo-EM structure (left) with the mFANCD2–FANCI crystal structure (PDB: 3S4W) (right). The mFANCD2–FANCI crystal structure
was ﬁltered to the same resolution as the 3D Cryo-EM model. Scale bar, 20Å. (d) Different orientations of Cryo-EM density map of full-length
FANCD2–FANCI complex docked with the mFANCD2–FANCI crystal structure (PDB: 3S4W). Scale bar, 20Å.
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FANCD2–FANCI complex and a replication fork DNA structure
containing an ICL, and that the interaction is dependent on the
Tower domain in FANCD2. We also know that the Tower
domain is required for monoubiquitination of FANCD2.
Therefore, we hypothesized that perhaps the reason the
FANCD2DTower is not ubiquitinated is that the protein is not
recruited to DNA, and therefore not ubiquitinated. If that were
the case, it could mean that FANCD2–FANCI has to be bound
to DNA to be ubiquitinated. To test this hypothesis, we
reconstituted the monoubiquitination reaction in vitro, using
recombinant proteins (Supplementary Fig. 4a). We then ﬁrst
assessed the monoubiquitination of FANCD2 in the absence of
DNA, and observed only very weak monoubiquitination (Fig. 4d,
lanes 2–4). However, when we added DNA to the reaction, a
robust monoubiquitination was observed (Fig. 4d, lanes 5–7),
consistent with a previous report11. The increase in speciﬁc
monoubiquitination was not due to increased general E3 ligase
activity in the reaction (Supplementary Fig. 4b). Interestingly, we
observed only modest monoubiquitination of FANCI, in good
agreement with previous reports (Supplementary Fig. 4c)11,12.
On the other hand, no monoubiquitination was observed when
we subjected the FANCD2DTower–FANCI complex to the same
assay (Fig. 4d, lanes 12–14). Taken together, this suggests that the
FANCD2–FANCI complex must be bound to DNA to be
activated by monoubiquitination, and that the Tower domain is
required for this mechanism. If the FANCD2–FANCI complex is
recruited to chromatin in its unmodiﬁed form, followed by
monoubiquitination ensuring strong retention on chromatin,
c
a
b
d
90° 180° 270°
Main
body
90° 180° 270°
Main
body Tower
(kDa)
200 -
116 -
97 -
- FANCD2ΔTower
- FANCI
- FANCD2
FA
NC
D2
–F
AN
CI
FA
NC
D2
ΔT
ow
er
–F
AN
CI
1,451
1
FANCD2N CTower
1,328
FANCIN C
1,146
FANCD2ΔTowerN C
FANCD2
FANCI
FANCD2ΔTower
1 K523
K561
Tower
1 2
Figure 2 | Determination of the Tower domain of FANCD2. (a) Schematic of FANCI and FANCD2 indicating the Tower domain. (b) Coomassie blue
stain of recombinant full-length FANCD2–FANCI and FANCD2DTower–FANCI heterodimer puriﬁed from Sf9 cells. (c) Different orientations of
Cryo-EM density map of the FANCD2DTower–FANCI complex. Scale bar, 20Å. (d) Different orientations of Cryo-EM density map of full-length
FANCD2–FANCI complex (in blue mesh) superimposed with the FANCD2DTower–FANCI complex (in gold). Scale bar, 20Å.
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we should be able to observe a weak recruitment in the
absence of ubiquitination. To test this directly, we assessed
the recruitment of a mutant of FANCD2 where the lysine that is
monoubiquitinated has been mutated, thereby preventing mono-
ubiquitination (FANCD2–K561R). EGFP–FANCD2–K561R was
stably expressed in HeLa cells where endogenous FANCD2 was
depleted by CRISPR-Cas9-mediated knockout (Supplementary
Fig. 5a). As expected, we observed a rapid and weak recruitment
of EGFP–FANCD2–K561R (Supplementary Fig. 5b,c). In the
same experiment, we observed no recruitment of EGFP–
FANCD2DTower. Taken together, these data reinforce a model
where the FANCD2–FANCI complex is recruited to ICLs via the
Tower domain, followed by monoubiquitination while bound to
DNA. Of particular interest, we found that three FA patients have
disease-causing mutations in the Tower domain13, underscoring
the functional importance of this domain (Fig. 4e).
Electrostatic interactions underlie the FANCD2-DNA binding.
To gain further mechanistic insight into how the FANCD2–
FANCI complex is recruited to replication forks stalled at ICLs,
we carefully analysed the primary amino acid sequence of the
Tower domain. Strikingly, we found two patches of positively
charged residues that are highly conserved (Supplementary
Fig. 6a,b). Inspection of the position of these residues in the
FANCD2–FANCI complex showed that they are located on the
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surface of the Tower domain (Fig. 5a,b). Therefore, we hypo-
thesized that these residues might be deﬁning the interaction of
the FANCD2–FANCI complex with the stalled replication fork
through electrostatic interactions. To test this directly, we created
two mutant versions of FANCD2, one where R1236 and K1247
are mutated and one where K1296, R1299 and K1307 are
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mutated, all to neutral alanines. We puriﬁed recombinant protein
complexes of these proteins with FANCI (Supplementary Fig. 6c)
and assessed their ability to interact with the ICL-containing
DNA structure mimicking a replication fork. As predicted, we
observed a signiﬁcantly reduced binding of the mutant containing
two mutated residues, and a nearly complete abrogation of
binding when all three residues were mutated (Fig. 5c). When we
subjected one of the mutants to the in vitro ubiquitination assay,
we observed a striking reduction of monoubiquitination, down to
the basal level observed in the absence of DNA (Fig. 5d, compare
lanes 4, 7 and 10). Since we observed such strong phenotypes
in vitro, we decided to verify the results in vivo. We ﬁrst assessed
the ability of the mutant protein to complement FANCD2 /
HeLa cells. As expected, FANCD2 containing the point mutations
abrogating DNA binding and ubiquitination in vitro, failed to
complement the cellular sensitivity (Fig. 5e). Similarly, when we
assessed the ability of this protein to be recruited to ICLs, a clear
defect was observed (Fig. 5f). Finally, when we assayed the
monoubiquitination status of the mutant version of FANCD2
after introduction of ICLs in live cells, a complete absence of
monoubiquitination was observed (Supplementary Fig. 6d).
Discussion
Activation of FANCD2 by monoubiquitination is an initial and
critical event in the FA DNA-repair pathway. The mechanism
underlying this process has remained elusive. Here, we present
the cryo-EM structure of the full-length human FANCD2–
FANCI complex, and uncover the existence of a novel Tower
domain of FANCD2. We demonstrate that the Tower domain is
required for a direct interaction with a DNA structure mimicking
a replication fork arrested at an ICL, and that this interaction
triggers the monoubiquitination event. Importantly, our work
determines that the FANCD2–FANCI complex is recruited to
DNA before it is monoubiquitinated, rather than what was
previously thought, namely that the monoubiquitination
precedes, and results in, recruitment of the complex to DNA14.
The cryo-EM structure of the human FANCD2–FANCI
complex is largely in agreement with the previously reported
crystal structure of the mouse homologues8. The only signiﬁcant
difference is the position of the Tower domain, which appears
vertical in our structure, and horizontal in the crystal structure.
There are several possible explanations for the difference. First, it
might be that the mouse and human proteins fold differently.
Second, three deletions were introduced in the mouse FANCD2
protein used for crystal formation, including a deletion of 59
residues at the base of the Tower. It is possible that this region
serves as a hinge, which upon deletion causes the Tower to adapt
a new conﬁrmation. Third, the FANCD2–FANCI complex used
in our structure determination was formed in vivo and puriﬁed as
a complex, whereas the mouse proteins were puriﬁed as
monomers and the complex assembled in vitro. Fourth, the
techniques used, hence the state of the protein samples used to
obtain the two structures, are principally different, which
might affect the conformation that the proteins adapt while
being analysed.
It is known that the FANCD2–FANCI complex possesses some
DNA-binding activity8,11,15; however, the true substrate during
ICL repair has remained elusive. Using puriﬁed components
we have discovered that the FANCD2–FANCI complex
preferentially binds to a DNA structure mimicking a replication
fork stalled at an ICL. This ﬁnding is in good agreement with
existing literature showing a function of the complex during
replication-dependent repair of ICLs16. We corroborated these
results by demonstrating a timely recruitment of FANCD2 to
ICLs in vivo.
Monoubiquitination of FANCD2 is essential to its function in
ICL repair. A point mutation of lysine 561 to arginine, leads to a
complete loss of function of the protein. However, the functional
consequence of this critical monoubiquitination is unknown. One
possibility is that the ubiquitination affects the ability of FANCD2
to be recognized by a protein facilitating the recruitment of
FANCD2 to DNA. If that were the case, it would entail that
FANCD2 is ubiquitinated before it is recruited to DNA, which is
indeed the current understanding. However, we found that
monoubiquitination of FANCD2 is strongly stimulated by DNA,
suggesting that the protein is ﬁrst recruited to DNA, likely
through binding to a replication fork stalled at an ICL, and
thereafter monoubiquitinated (Fig. 5g). Indeed, it has been shown
that the FA core complex, that is, the E3 ligase responsible for
monoubiquitinating FANCD2, is recruited to chromatin via
FANCM and FAAP24 (refs 17,18), consistent with the notion
that ubiquitination takes place on DNA18,19. It is possible that
the FANCD2–FANCI complex undergoes a conformational
change upon binding to the ICL, and that this allows the
monoubiquitination to take place. Ongoing structural studies
should clarify this. It is possible that after FANCD2–FANCI is
monoubiquitinated it acquires even higher afﬁnity for the ICL.
It is also plausible that the monoubiquitinated form of
FANCD2–FANCI interacts with a chromatin-associated factor,
ensuring retention after its modiﬁcation.
Methods
Cell lines and antibodies. HeLa (originally from ATCC) and PD20 (kindly
provided by the FARF repository) cells were grown in DMEM (D5796, Sigma)
supplemented with 2.5–10% fetal bovine serum. Antibodies used were as follows:
anti-FANCD2, 1:100 dilution (sc-20022, Santa Cruz Biotechnology); anti-FANCI,
1:1,000 dilution (FARF); anti-FANCA, 1:1,000 dilution (FARF); anti-Lamin B,
1:1,000 dilution (sc-6216, Santa Cruz Biotechnology); anti-Flag, 1:1,000 dilution
(M5, F4042, Sigma-Aldrich); anti-Ubiquitin, 1:400 dilution (FK2,BML-PW8810,
Enzo Life Sciences); anti-UHRF1, 1:1,000 dilution (sc-373750, Santa Cruz Bio-
technology); and anti-a-Tubulin, 1:2,000 dilution (5829, Millipore).
Plasmids and transfection. EGFP-fused FANCD2 cDNA was expressed using the
pOZ-N plasmid10. shRNA-mediated knockdown of the FANCD2 gene was
achieved by expressing the target sequence 50-GAGCAAAGCCACTGAGGTA-30
in the pSuper.retro vector (Clontech). Transfections of plasmid DNA were carried
out using FuGENE6 (Promega) according to the manufacturer s instructions.
The FANCD2DTower mutant protein was generated by deleting amino acids
1,147–1,451 from the full-length protein. Uncropped images of the original
Western blots are shown in Supplementary Fig. 7.
CRISPR-Cas9 gene editing. The targeting sequence used in the sgRNA was:
50-GTTTGTCTTGTGAGCGTCTGC-30 . HeLa-FANCD2 / cells were
generated using plasmid pX459 (Addgene #48139) as follows20: primers,
50-CACCGTTTGTCTTGTGAGCGTCTGC-30 and 50-AAACGCAGACGCTCAC
AAGACAAAC-30 , were annealed and introduced into the pX459 plasmid through
its BbsI site. HeLa cells were transfected with 2 mg of the resulting pX459 plasmid
and selected with 4 mgml 1 puromycin after 24 h. After another 24 h, cells were
plated at low density and clones were picked after 2 weeks. Clones were analysed
using immunoblot analysis.
Protein puriﬁcation. FANCD2 and UBA1 were expressed using the pFastBac1
vector (Life Technologies) with an engineered N-terminal Flag-HA tag, and
FANCL was expressed using the pFastBac1 vector (Life Technologies) with an
engineered N-terminal Flag-MBP tag or a N-terminal Flag-HA tag. For FANCD2–
FANCI complex, Sf9 cell pellets were re-suspended in lysis buffer (20mM Tris-HCl
pH 8.0, 0.1M KCl, 10% glycerol and 0.2mM PMSF), and sonicated. Lysates were
clariﬁed by centrifugation (17,000g), and the supernatants were incubated with M2
anti-FLAG agarose resin (A2220, Sigma) for 2 h. The resin was washed carefully,
and the protein was eluted in the same buffer containing 0.5mgml 1 FLAG
peptide. The ﬂag eluate was supplemented with 20mM Imidazole and incubated
with Ni2þ -NTA (30310, QIAGEN) at 4C for 2 h with rotation. The resin was
washed carefully, and eluted with buffer containing 20mM Tris (pH 8.0), 0.1M
KCl, 250mM Imidazole, 0.2mM PMSF and 10% glycerol. The Ni2þ -NTA eluate
was injected into pre-equilibrated size-exclusion chromatography column, Super-
dex 200, and eluted with the base buffer containing 20mM Tris (pH 8.0), 0.1M
KCl and 5% glycerol. The FANCD2DTower-FANCI complex is puriﬁed as full-
length FANCD2–FANCI except the size-exclusion chromatography step. UBA1
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and FANCL are puriﬁed against FLAG tag described as above. UBE2t expressing
plasmid was a kind gift from Dr. Helen Walden, where in brief, UBE2t was cloned
into a pET based expression vector containing an N-terminal 6xHis-Smt3 tag.
UBE2t was expressed in E. coli BL21(DE3) (Novagen). Cells were grown in
Lysogeny Broth supplemented with antibiotics at 37 C. Expression of UBE2t was
induced at OD600¼ 0.6 with 0.5mM IPTG, and cultured overnight at 16 C.
Harvested cells were lysed by french press in the buffer containing 0.5M NaCl,
0.1M Tris (pH 8), 0.02M Imidazole, and 0.25mM TCEP. The lysate was clariﬁed
by centrifugation (48,000g), and the supernatant was incubated with Ni-NTA
Agarose (QIAGEN) for 2 hours at 4 C. 6xHis-Smt3 tag was removed overnight at
4 C by Ulp1 protease at a w/w ratio of 1:15, Ulp1:UBE2t. UBE2t was concentrated,
and loaded onto a Superdex 200 column with 200mM NaCl, 0.1M Tris (pH 8) and
10% glycerol. The described UBE2t puriﬁcation is a derivative of a previously
published method21.
EM and 3D image processing. Negatively stained freshly prepared full-length
FANCD2–FANCI was applied to glow-discharged, carbon-coated grids and
allowed to adsorb for 15–60 s. Specimen was then stained with 2% uranyl acetate.
Vitriﬁed full-length FANCD2–FANCI and FANCD2DTower–FANCI was pre-
pared on glow-discharged carbon-coated quantifoil grids. Specimen were imaged at
a nominal magniﬁcation of 30,000 with a 2 k 2 k Gatan CCD camera
(corresponding to a pixel size of 3.5 Å at the specimen level) in a JEOL 2100, LaB6
operating at 200 kV. A preliminary full-length FANCD2–FANCI 3D model was
calculated using the RCT9 and the WEB and SPIDER software package22. For this
ﬁrst 3D model, 4,082 pairs of particles of full-length FANCD2–FANCI were picked
from 80 tilt pair images recorded at 50 and 0. Reﬁnement of the 3D volume
obtained from the RCT method was done using images from frozen, hydrated, full-
length FANCD2–FANCI. In all, 5,058 particles were selected after using Roseman’s
algorithm23 in SPIDER22 procedure, and subsequently manual selection in WEB22.
Defocus was determined using CTFTILT24. 3D classiﬁcation and reﬁnement
were carried out in RELION25, with 25 iterations of 1 class and 4 classes 3D
classiﬁcation. For the FANCD2DTower–FANCI complex, frozen particles were
selected using Roseman’s algorithm23 in a SPIDER22 procedure, with the previous
frozen, hydrated, full-length FANCD2–FANCI structure, and then manually
screened using the EMAN26 program Boxer. In all, 8,547 particles were selected
from 71 micrographs with a defocus range of 3–5.2 mm. Defocus was determined
using CTFFIND3 (ref. 24). Reﬁnement was carried out using EMAN26 software
package. The frozen, hydrated, full-length FANCD2–FANCI structure was used as
the starting model and reﬁned against the FANCD2DTower–FANCI particles. At
each iteration, particles with bad cross-correlation values were temporally removed,
and intermediate volume was band-pass ﬁltered between 10 and 150Å. For the
resolution limit estimation of 3D-reconstruction volumes, two independent
reconstructions were carried out and compared in reciprocal space using increasing
shells with the FSC (Fourier shell correlation) technique. Visualization of
3D-density map was done in UCSF Chimera27.
Preparation of interstrand crosslinked DNA substrates. The DNA oligos were
annealed in a buffer containing 10mM Tris-HCl pH 7.5, 100mM NaCl and 1mM
EDTA. 4,50 ,8-trimethylpsoralen (TMP, Sigma, T6137) crosslinking was carried out
using 2.6 mM annealed DNA in crosslinking buffer (10mM Tris-HCl pH 7.5, 1mM
EDTA, and 50mM NaCl) with 87.6 mM TMP. The reaction was done using a UVA
source (4.2mWm 2) wavelength of 365 nm for 6 cycles at 15-min intervals. Our
protocol is a modiﬁcation of a previously published method28. ICL was conﬁrmed
by 8M urea 12% denaturing polyacrylmide gel electrophoresis. ICL14FF was
created by annealing the following DNA oligonucleotides: ICL14 (þ ): 50-CAT
TGTGAATTCGCCTCTCTGTCTAGCCGAAGCTCGAAACGATCTTGTGC-30 ;
ICL14 ( ): 50-GTCCATCAAAGTTCGACTGTGCGGCTAGACAGAGAGGCG
AATTCACAATG-30 , ICL14 leading: 50-GCACAAGATCGTTTCGAGCTT-30 ,
ICL14 lagging: 50-GTCGAACTTTGATGGAC-30 . The bases part of the ICL are
indicated in bold.
Electrophoretic mobility shift assay. The protein–DNA-binding reaction that
contained 0.5 mg of FANCD2–FANCI complex, or derivative thereof, and 1 nM
radiolabeled DNA, was performed in 10 ml containing 25mM Tris-HCl pH 7.5,
100mM NaCl, 6% glycerol and 1mM dithiothreitol. The reaction mixture was
incubated at room temperature for 1 h. For super-shift, 0.5 mg anti-HA antibody
was added, and incubated for another 1 h. For the experiment in Fig. 4c the
following amounts of protein were used: 0, 0.125, 0.25 and 0.5 mg. After the
incubation, the reaction mixtures were loaded onto a 0.4TBE, 4% poly-
acrylamide gel, and run with 0.4TBE buffer at 4 C. The gel was then ﬁxed with
10% methanol/10% acetic acid for 5min, dried and exposed to ﬁlm or photo-
stimulable phosphor imaging plate.
Live-cell imaging. EGFP-fused wild-type and mutant FANCD2 or mCherry-fused
UHRF1 cDNA were inserted into the pOZ vector as described above. Live-cell
imaging were carried out with an OLYMPUS IX81 microscope connected to
PerkinElmer UltraView Vox spinning-disk system equipped with a Plan-Apoc-
hromat 60 /1.4 oil objective using Volocity software 6.3 for image capturing.
EGFP was excited with 488-nm laser lines. Throughout the experiment, these cells
were maintained at 5% CO2, and 37 C using a live-cell environmental chamber
(Tokai hit). Confocal image series were typically recorded with a frame size of
512 512 pixels and a pixel size of 139 nm. For localized DNA-damage induction,
cells were seeded in glass-bottom dish (MatTek) and sensitized by incubation in
DMEM supplemented with 10% fetal bovine serum and 20 mgml 1 TMP for
30min at 37 C. Microirradiation was performed using the FRAP preview mode of
the Volocity software by scanning (each irradiation time was 100ms) a pre-selected
3–5 stripes (50 3 pixels) within the nucleus 10–60 times with a 405-nm laser set
to 100% laser power. The EGFP and mCherry intensities at micro-irradiated sites
were quantiﬁed using ImageJ with Fiji, and normalized by their intensities before
microirradiation.
Cell fractionation and whole-cell lysate. Collected cell pellets were permeabilized
with CSK buffer containing 200mM NaCl, 10mM PIPES, 300mM Sucrose, 1mM
MgCl2, 1mM EDTA and 0.5% Triton X-100 on ice for 10min. CSK fraction
(supernatant) and nuclear pellet were separated by centrifugation at 900g at 4C for
10min. Nuclear pellet was processed the same way as whole-cell lysate described
below. Preparation of whole-cell lysate was performed by scraping off cells from
dishes followed by centrifugation at 100g for 5min. Cell pellets were re-suspended
and incubated in an equal volume of Benzonase buffer (2mM MgCl2, 20mM
Tris-HCl (pH 8.0), 10% glycerol, 1% Triton X-100 and 12.5 Uml 1 Benzonase
(E1014, Sigma-Aldrich) on ice for 10min. The cells were then lysed by addition of
an equal volume of 2% SDS to reach a ﬁnal concentration of 1%. Samples were
heated at 70 C for 2min. The protein concentration was determined by the
Bradford assay (Bio-Rad Life Science).
Clonogenic survival assay. Cells (250–4,000) were plated in six-well plates and
treated with different dosages of MMC on the next day. Colony formation was
scored after 10–14 days using 1% (w/v) crystal violet in methanol.
Co-immunoprecipitation. PD20 and PD20-expressing FLAG-HA-tagged
FANCD2 and FANCD2DTower cells were treated with 160 ngml 1 MMC over-
night. Cell pellets were incubated with Buffer A (0.5% Triton X-100, 20mM
Tris pH 8.0, 2mM MgCl2, 5mM MgCl2, 10% Glycerol, 50U ml 1 Benzonase for
10min on ice. Ten times the pellet volume of Buffer B (0.5% Triton X-100, 20mM
Tris-HCl pH 8.0, 2mM MgCl2, 10% Glycerol, 150mM KCl and 0.2mM PMSF)
was added to the mixture and incubated for 10min for extraction. Lysates were
clariﬁed by centrifugation (17,000g), and supernatant was used for immunopre-
cipitation. M2 agarose beads were added to the lysates, and incubated for 2 h. The
resin was washed extensively, and eluted with 0.5mgml 1 FLAG peptide.
In vitro ubiquitination assay. Reaction volumes of 25 ml contained 17 nM UBA1,
0.64mM UBE2T, 0.372mM FANCL or FLAG-HA-FANCL, 4.2mM His-Ub,
0.25mM FANCD2–FANCI complex or derivatives thereof, 20mM pBlueScript
SKII (þ ) when indicated, in the following reaction buffer: 50mM Tris (pH 7.5),
100mM KCl2, 2mM MgCl2, 0.5mM dithiothreitol and 2mM ATP. Reactions were
incubated at room temperature for the indicated time. In all, 5 ml of 6 SDS
loading buffer containing BME was used to terminate reactions. Samples were
loaded onto an SDS-PAGE gel and subjected to Coomassie blue staining or
immunoblotting. The described in vitro ubiquitination assay is a derivative of a
previously published method21.
Data availability. Cryo-EM reconstructions of the FANCD2–FANCI and
FANCD2DTower–FANCI complexes are deposited to the EMDB database under
accession numbers EMD-8141 and EMD-8142, respectively.
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